常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.35/0.76
|
|
企业价值
15.21B
|
| 资产负债 |
|
每股账面净值
13.20
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
2.76B
|
|
每股收益
12.70
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/08 12:21 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, aliquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |

66.18 
